Progress towards therapies for disease modification in Parkinson's disease

The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifyi...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2021-07, Vol.20 (7), p.559-572
Main Authors: Vijiaratnam, Nirosen, Simuni, Tanya, Bandmann, Oliver, Morris, Huw R, Foltynie, Thomas
Format: Article
Language:English
Subjects:
Clinical trials
Failure
Intervention
Medical treatment
Movement disorders
Neurodegeneration
Neurodegenerative diseases
Parkinson's disease
Pathogenesis
Patients
Precision medicine
Quality of life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches for the selection of therapeutic candidates but also to insufficient attention to detail in clinical trial design. Better understanding of Parkinson's disease pathogenesis associated with advances in laboratory models, the use of objective biomarkers of disease progression and target engagement, and a focus on agents known to be safe for human use, alongside the use of precision medicine approaches, should together greatly increase the likelihood for successful identification of disease-modifying treatments for Parkinson's disease.
ISSN:1474-4422
1474-4465
DOI:10.1016/S1474-4422(21)00061-2